Produodopa 240 mg/ml + 12 mg/ml otopina za infuziju Хорватія - хорватська - HALMED (Agencija za lijekove i medicinske proizvode)

produodopa 240 mg/ml + 12 mg/ml otopina za infuziju

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - foslevodopa foskarbidopa - otopina za infuziju - urbroj: 1 ml otopine sadrži 240 mg foslevodope (što odgovara približno 170 mg levodope) i 12 mg foskarbidope (što odgovara približno 9 mg karbidope) 10 ml otopine sadrži 2400 mg foslevodope (što odgovara približno 1700 mg levodope) i 120 mg foskarbidope (što odgovara približno 90 mg karbidope)

Yttriga Європейський Союз - хорватська - EMA (European Medicines Agency)

yttriga

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - radionuklidno slikanje - dijagnostički radiofarmaceutici - upotrebljava se samo za radioaktivno obilježavanje molekula nosača, koji su posebno razvijeni i ovlašteni za radioaktivno obilježavanje s ovim radionuklidom. Радиофармацевтический прекурсор - nije namijenjen za izravnu uporabu u bolesnika.

SevoFlo Європейський Союз - хорватська - EMA (European Medicines Agency)

sevoflo

zoetis belgium sa - sevofluran - anestetici, opće - dogs; cats - za indukciju i održavanje anestezije kod pasa i mačaka.

Synagis Європейський Союз - хорватська - EMA (European Medicines Agency)

synagis

astrazeneca ab - palivizumab - infekcije respiratornih sincicijskih virusa - imuni serumi i homologna, - Синагис je indiciran za prevenciju ozbiljnih donjih dišnih bolesti, koje zahtijevaju hospitalizaciju, uzrokovane респираторно-синцитиальный virus (РСВ) u djece s visokim rizikom za razvoj РСВ bolesti:djeca rođena u 35 tjednu trudnoće ili manje i manje od šest mjeseci od početka sezone РСВ;dijete manje od dvije godine i potrebitima u liječenju бронхолегочной displazije u posljednjih šest mjeseci;djeca u dobi do dvije godine s hemodinamski značajnim prirođene srčane.

Rinvoq Європейський Союз - хорватська - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.